Maze Therapeutics
- Market cap
- 1.46B
- P/E (TTM)i
- -10.91
- P/Bi
- 3.22
- EPSi
- -2.66
- Div yieldi
- 0.00%
- 52W posi
- 14%
Anonymous reader poll. Unscientific, not investment advice.
About Maze Therapeutics
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.
- Founded
- 2017
- CEO
- Dr. Jason V. Coloma, PhD
- Employees
- 141
- Headquarters
- San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- mazetx.com
Company profile
- Exchange
- US
- Symbol
- MAZE
- Market-cap rank
- #2998
- Listing date
- 2025-01-31
- Market cap
- 1.46B
- Float cap
- 977.82M
- Shares out
- 55.55M
- Float shares
- 37.25M
Sectors & themes
Quote time 2026-10-08 04:44:40 · For reference only, not investment advice and not tailored to your situation.